Inflammatory bowel diseases (IBD) are chronic, remitting, and relapsing conditions of the gastrointestinal tract with incompletely elucidated etiology. The anti-TNF-伪 mAbs represent one of aflash nanocomplexation and flash nanoprecipitation process, resulting in particles with a narrow size distribution ...
Anti-TNF therapy can induce and maintain a remission status during intestinal bowel disease. However, up to 30% of patients do not respond to this therapy by mechanisms that are unknown. Here, we show that the absence of MCJ, a natural inhibitor of the respiratory chain Complex I, induces ...
Intravenous infusion of Infliximab (Remicade, Centocor Inc., Malvern, PA), a monoclonal chimeric anti-TNF antibody, was the first and currently best studied Food and Drug Administration-approved anti-TNF therapy for Crohn's disease and ulcerative colitis.4–7 Although repeated intravenous admin- ...
In the field of RA treatment, significant progress has been achieved with the introduction of anti-TNF biologic therapy [8]. Although TNF-blockade therapy constitutes a spectacular advance in the RA treatment, approximately one-third of patients do not respond to this therapeutic approach [9,10]....
Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have revolutionized the therapy of immune-mediated inflammatory disea
Treatment for ulcerative colitis can consist of medications and/or surgery. Receiving both has raised concerns in their role in causing adverse effects.
Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis作者:Huguet, Mathilde; Pereira, Bruno; Goutte, Marion; Goutorbe, Felix; Dubois, Anne; Bommel...
(2) The immunophenotype was also compared between long-term anti-TNF treated-responders and non-responders (cross-sectional study). The results were compared with those of therapy-nave patients with active disease and those in remission with non-biological immunosuppressive therapy, and with healthy ...
Tumour necrosis factor α (TNF-α) is a pivotal factor in the disordered inflammatory response that characterizes diseases such as CD and ulcerative colitis (UC). The action of this cytokine is highly complex, though it is known to be mainly proinflammatory.1, 14 As a result, TNF-α drives...
Anti-TNF agents (ATAs) are generally the first-line biological therapy in ulcerative colitis (UC) patients who have failed treatment with corticosteroids and/or immunomodulators. Patients with non-response/loss of response with ATAs undergo treatment switch or colectomy/surgery. We assessed the rates...